180 related articles for article (PubMed ID: 12914745)
61. Role of medical therapy in the management of acromegaly.
Vance ML; Laws ER
Neurosurgery; 2005 May; 56(5):877-85; discussion 877-85. PubMed ID: 15854234
[TBL] [Abstract][Full Text] [Related]
62. Lessons learned from studies with the growth hormone receptor.
Kopchick JJ
Growth Horm IGF Res; 2016 Jun; 28():21-5. PubMed ID: 26216709
[TBL] [Abstract][Full Text] [Related]
63. Treatment of pituitary tumors: pegvisomant.
Paisley AN; Drake WM
Endocrine; 2005 Oct; 28(1):111-4. PubMed ID: 16311417
[TBL] [Abstract][Full Text] [Related]
64. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
[TBL] [Abstract][Full Text] [Related]
65. Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly.
Parkinson C; Drake WM; Wieringa G; Yates AP; Besser GM; Trainer PJ
Clin Endocrinol (Oxf); 2002 Mar; 56(3):303-11. PubMed ID: 11940041
[TBL] [Abstract][Full Text] [Related]
66. Long-term effects of pegvisomant in patients with acromegaly.
Hodish I; Barkan A
Nat Clin Pract Endocrinol Metab; 2008 Jun; 4(6):324-32. PubMed ID: 18431372
[TBL] [Abstract][Full Text] [Related]
67. Long-term treatment with pegvisomant as monotherapy in patients with acromegaly: experience from ACROSTUDY.
Freda PU; Gordon MB; Kelepouris N; Jonsson P; Koltowska-Haggstrom M; van der Lely AJ
Endocr Pract; 2015 Mar; 21(3):264-74. PubMed ID: 25370326
[TBL] [Abstract][Full Text] [Related]
68. Long-term efficacy and safety of pegvisomant therapy in acromegaly.
Yuen KC; Katznelson L
Endocr Pract; 2015 Mar; 21(3):296-8. PubMed ID: 25667381
[No Abstract] [Full Text] [Related]
69. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
[TBL] [Abstract][Full Text] [Related]
70. [Growth hormone receptor antagonists: potential indications].
Muller AF; Janssen JA; de Herder WW; van der Lely AJ
Ned Tijdschr Geneeskd; 2001 Jan; 145(2):69-73. PubMed ID: 11225259
[TBL] [Abstract][Full Text] [Related]
71. Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis.
Leonart LP; Ferreira VL; Tonin FS; Fernandez-Llimos F; Pontarolo R
Value Health; 2018 Jul; 21(7):874-880. PubMed ID: 30005760
[TBL] [Abstract][Full Text] [Related]
72. Control of tumor size and disease activity during cotreatment with octreotide and the growth hormone receptor antagonist pegvisomant in an acromegalic patient.
van der Lely AJ; Muller A; Janssen JA; Davis RJ; Zib KA; Scarlett JA; Lamberts SW
J Clin Endocrinol Metab; 2001 Feb; 86(2):478-81. PubMed ID: 11157994
[TBL] [Abstract][Full Text] [Related]
73. Effect of treatment with pegvisomant on meningioma growth in vivo.
Drake WM; Grossman AB; Hutson RK
Eur J Endocrinol; 2005 Jan; 152(1):161-2. PubMed ID: 15762200
[No Abstract] [Full Text] [Related]
74. Long-term treatment with pegvisomant for acromegaly: a 10-year experience.
Ramos-Leví AM; Bernabeu I; Álvarez-Escolá C; Aller J; Lucas T; de Miguel P; Rodríguez-Cañete L; Sampedro-Núñez MA; Halperin I; Puig-Domingo M; Marazuela M
Clin Endocrinol (Oxf); 2016 Apr; 84(4):540-50. PubMed ID: 26662620
[TBL] [Abstract][Full Text] [Related]
75. Treatment of acromegaly.
Utiger RD
N Engl J Med; 2000 Apr; 342(16):1210-1. PubMed ID: 10770989
[No Abstract] [Full Text] [Related]
76. Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant.
Strasburger CJ; Mattsson A; Wilton P; Aydin F; Hey-Hadavi J; Biller BMK
Eur J Endocrinol; 2018 Apr; 178(4):321-329. PubMed ID: 29371335
[TBL] [Abstract][Full Text] [Related]
77. Growth hormone receptor antagonists.
Kohn DT; Kopchick JJ
Minerva Endocrinol; 2002 Dec; 27(4):287-98. PubMed ID: 12511851
[TBL] [Abstract][Full Text] [Related]
78. [Drug therapy of acromegaly].
Krankenpfl J; 2004; 42(7-10):260-1. PubMed ID: 15675419
[No Abstract] [Full Text] [Related]
79. Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm.
Clemmons DR; Chihara K; Freda PU; Ho KK; Klibanski A; Melmed S; Shalet SM; Strasburger CJ; Trainer PJ; Thorner MO
J Clin Endocrinol Metab; 2003 Oct; 88(10):4759-67. PubMed ID: 14557452
[TBL] [Abstract][Full Text] [Related]
80. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist.
van der Lely AJ; Hutson RK; Trainer PJ; Besser GM; Barkan AL; Katznelson L; Klibanski A; Herman-Bonert V; Melmed S; Vance ML; Freda PU; Stewart PM; Friend KE; Clemmons DR; Johannsson G; Stavrou S; Cook DM; Phillips LS; Strasburger CJ; Hackett S; Zib KA; Davis RJ; Scarlett JA; Thorner MO
Lancet; 2001 Nov; 358(9295):1754-9. PubMed ID: 11734231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
